

Jingyou Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2766196/publications.pdf>

Version: 2024-02-01

59
papers

8,915
citations

159358

30
h-index

128067

60
g-index

78
all docs

78
docs citations

78
times ranked

13352
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634.	13.7	995
2	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020, 369, 806-811.	6.0	978
3	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817.	6.0	789
4	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	13.7	765
5	Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. <i>Science Immunology</i> , 2020, 5, .	5.6	561
6	Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. <i>New England Journal of Medicine</i> , 2022, 387, 86-88.	13.9	433
7	Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. <i>Immunity</i> , 2020, 53, 524-532.e4.	6.6	334
8	Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. <i>Nature</i> , 2022, 603, 493-496.	13.7	326
9	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2370.	3.8	307
10	Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. <i>New England Journal of Medicine</i> , 2022, 386, 1579-1580.	13.9	296
11	Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	13.7	290
12	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , 2020, 26, 1694-1700.	15.2	275
13	Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. <i>Cell</i> , 2020, 183, 1508-1519.e12.	13.5	263
14	Immunogenicity of the Ad26.COVS Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
15	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2021, 385, 2010-2012.	13.9	228
16	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COVS Vaccination. <i>New England Journal of Medicine</i> , 2021, 385, 951-953.	13.9	192
17	IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein. <i>Cell Reports</i> , 2015, 13, 145-156.	2.9	133
18	Approaches and Challenges in SARS-CoV-2 Vaccine Development. <i>Cell Host and Microbe</i> , 2020, 28, 364-370.	5.1	98

#	ARTICLE	IF	CITATIONS
19	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. <i>Nature Communications</i> , 2021, 12, 1018.	5.8	82
20	Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. <i>Journal of Virology</i> , 2021, 95, .	1.5	80
21	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	13.7	71
22	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	68
23	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.	13.5	59
24	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
25	Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. <i>Science Translational Medicine</i> , 2022, 14, eabn6150.	5.8	57
26	Interferon-inducible LY6E Protein Promotes HIV-1 Infection. <i>Journal of Biological Chemistry</i> , 2017, 292, 4674-4685.	1.6	52
27	Low-dose Ad26.COVS protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11.	13.5	49
28	Protective efficacy of Ad26.COVS against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	13.7	40
29	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. <i>JCI Insight</i> , 2021, 6, .	2.3	39
30	The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity. <i>Journal of Virology</i> , 2017, 91, .	1.5	37
31	Emerging Role of LY6E in Virus-Host Interactions. <i>Viruses</i> , 2019, 11, 1020.	1.5	37
32	Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. <i>Journal of Virology</i> , 2021, 95, e0040421.	1.5	34
33	Immunity elicited by natural infection or Ad26.COVS vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj3789.	5.8	32
34	TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 5705-5714.	3.3	28
35	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques. <i>Science Advances</i> , 2022, 8, eabl6015.	4.7	27
36	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection. <i>Journal of Virology</i> , 2021, 95, .	1.5	24

#	ARTICLE	IF	CITATIONS
37	Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV. PLoS ONE, 2016, 11, e0156739.	1.1	23
38	CD4-Dependent Modulation of HIV-1 Entry by LY6E. Journal of Virology, 2019, 93, .	1.5	22
39	SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COVS2.S vaccination predict durable protection in rhesus macaques. Nature Communications, 2021, 12, 5877.	5.8	21
40	Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2. Science Advances, 2021, 7, eabj6538.	4.7	19
41	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. Science Translational Medicine, 2021, 13, eabj2641.	5.8	15
42	Epidemiological and Immunological Features of Obesity and SARS-CoV-2. Viruses, 2021, 13, 2235.	1.5	15
43	Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. Journal of Infectious Diseases, 2022, 225, 1124-1128.	1.9	15
44	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. PLoS Biology, 2022, 20, e3001609.	2.6	14
45	Relating GPI-Anchored Ly6 Proteins uPAR and CD59 to Viral Infection. Viruses, 2019, 11, 1060.	1.5	13
46	SERINC proteins potentiate antiviral type I IFN production and proinflammatory signaling pathways. Science Signaling, 2021, 14, eabc7611.	1.6	13
47	A homologous or variant booster vaccine after Ad26.COVS2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. Science Translational Medicine, 2022, 14, eabm4996.	5.8	13
48	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. Journal of Virology, 2021, 95, e0097421.	1.5	12
49	Protective efficacy of an attenuated Mtb Δ LprG vaccine in mice. PLoS Pathogens, 2020, 16, e1009096.	2.1	12
50	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. Med, 2022, 3, 188-203.e4.	2.2	11
51	The Inhibition of HIV-1 Entry Imposed by Interferon Inducible Transmembrane Proteins Is Independent of Co-Receptor Usage. Viruses, 2018, 10, 413.	1.5	10
52	A Modular Biomaterial Scaffold-Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS-CoV-2 Antigens. Advanced Healthcare Materials, 2021, 10, e2101370.	3.9	10
53	Durability and expansion of neutralizing antibody breadth following Ad26.COVS2.S vaccination of mice. Npj Vaccines, 2022, 7, 23.	2.9	6
54	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. Journal of Virology, 2022, 96, JVI0159921.	1.5	5

#	ARTICLE	IF	CITATIONS
55	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2021, , eabj5305.	5.8	4
56	Fighting Fire with Fire: Immunogenicity of Viral Vected Vaccines against COVID-19. <i>Viruses</i> , 2022, 14, 380.	1.5	4
57	A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	3
58	Passive transfer of Ad26.COv2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. <i>Npj Vaccines</i> , 2022, 7, 2.	2.9	2
59	Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments. <i>Veterinary Pathology</i> , 2022, , 030098582210957.	0.8	2